In a brief talk, Bachelet said DNA nanobots will soon be tried in a critically ill leukemia patient. The patient, who has been given roughly six months to live, will receive an injection of DNA nanobots designed to interact with and destroy leukemia cells—while causing virtually zero collateral damage in healthy tissue.
According to Bachelet, his team have successfully tested their method in cell cultures and animals and written two papers on the subject, one in Science and one in Nature.
Contemporary cancer therapies involving invasive surgery and blasts of drugs can be as painful and damaging to the body as the disease itself. If Bachelet’s approach proves successful in humans, and is backed by more research in the coming years, the team’s work could signal a transformational moment in cancer treatment.
If this treatment works this will be a medical breakthrough and can be used for many other diseases by delivering drugs more effectively without causing side effects.
2012 Video with answers from George Church, Ido Bachelet and Shawn Douglas on the medical DNA double helix clamshell nanobucket nanobot
George Church indicates the smart DNA nanobot has applications beyond nanomedicine. Applications where there is any need for programmable and targeted release or interaction at the cellular or near molecular scale.
2014 Geek Time Presentation from Ido Bachelet
At the British Friends of Bar-Ilan University’s event in Otto Uomo October 2014 Professor Ido Bachelet announced the beginning of the human treatment with nanomedicine. He indicates DNA nanobots can currently identify cells in humans with 12 different types of cancer tumors.
A human patient with late stage leukemia will be given DNA nanobot treatment. Without the DNA nanobot treatment the patient would be expected to die in the summer of 2015. Based upon animal trials they expect to remove the cancer within one month.
Within 1 or 2 years they hope to have spinal cord repair working in animals and then shortly thereafter in humans. This is working in tissue cultures.
Previously Ido Bachelet and Shawn Douglas have published work on DNA nanobots in the journal Nature and other respected science publications.
One Trillion 50 nanometer nanobots in a syringe will be injected into people to perform cellular surgery.
The DNA nanobots have been tuned to not cause an immune response.
They have been adjusted for different kinds of medical procedures. Procedures can be quick or ones that last many days.
Medicine or treatment released based upon molecular sensing – Only targeted cells are treated
Ido’s daughter has a leg disease which requires frequent surgery. He is hoping his DNA nanobots will make the type of surgery she needs relatively trivial – a simple injection at a doctor’s office.
We can control powerful drugs that were already developed
Effective drugs that were withdrawn from the market for excessive toxicity can be combined with DNA nanobots for effective delivery. The tiny molecular computers of the DNA nanobots can provide molecular selective control for powerful medicines that were already developed.
Using DNA origami and molecular programming, they are reality. These nanobots can seek and kill cancer cells, mimic social insect behaviors, carry out logical operators like a computer in a living animal, and they can be controlled from an Xbox. Ido Bachelet from the bio-design lab at Bar Ilan University explains this technology and how it will change medicine in the near future.
Ido Bachelet earned his Ph.D. from the Hebrew University in Jerusalem, and was a postdoctoral fellow at M.I.T. and Harvard University. He is currently an assistant professor in the Faculty of Life Sciences and the Nano-Center at Bar Ilan University, Israel, the founder of several biotech companies, and a composer of music for piano and molecules.
Researchers have injected various kinds of DNA nanobots into cockroaches. Because the nanobots are labelled with fluorescent markers, the researchers can follow them and analyse how different robot combinations affect where substances are delivered. The team says the accuracy of delivery and control of the nanobots is equivalent to a computer system.
This is the development of the vision of nanomedicine.
This is the realization of the power of DNA nanotechnology.
This is programmable dna nanotechnology.
The DNA nanotechnology cannot perform atomically precise chemistry (yet), but having control of the DNA combined with advanced synthetic biology and control of proteins and nanoparticles is clearly developing into very interesting capabilities.
“This is the first time that biological therapy has been able to match how a computer processor works,” says co-author Ido Bachelet of the Institute of Nanotechnology and Advanced Materials at Bar Ilan University.
The team says it should be possible to scale up the computing power in the cockroach to that of an 8-bit computer, equivalent to a Commodore 64 or Atari 800 from the 1980s. Goni-Moreno agrees that this is feasible. “The mechanism seems easy to scale up so the complexity of the computations will soon become higher,” he says.
An obvious benefit of this technology would be cancer treatments, because these must be cell-specific and current treatments are not well-targeted. But a treatment like this in mammals must overcome the immune response triggered when a foreign object enters the body.
Bachelet is confident that the team can enhance the robots’ stability so that they can survive in mammals. “There is no reason why preliminary trials on humans can’t start within five years,” he says
Biological systems are collections of discrete molecular objects that move around and collide with each other. Cells carry out elaborate processes by precisely controlling these collisions, but developing artificial machines that can interface with and control such interactions remains a significant challenge. DNA is a natural substrate for computing and has been used to implement a diverse set of mathematical problems, logic circuits and robotics. The molecule also interfaces naturally with living systems, and different forms of DNA-based biocomputing have already been demonstrated. Here, we show that DNA origami can be used to fabricate nanoscale robots that are capable of dynamically interacting with each other in a living animal. The interactions generate logical outputs, which are relayed to switch molecular payloads on or off. As a proof of principle, we use the system to create architectures that emulate various logic gates (AND, OR, XOR, NAND, NOT, CNOT and a half adder). Following an ex vivo prototyping phase, we successfully used the DNA origami robots in living cockroaches (Blaberus discoidalis) to control a molecule that targets their cells.
Ido Bachelet’s moonshot to use nanorobotics for surgery has the potential to change lives globally. But who is the man behind the moonshot?
Ido graduated from the Hebrew University of Jerusalem with a PhD in pharmacology and experimental therapeutics. Afterwards he did two postdocs; one in engineering at MIT and one in synthetic biology in the lab of George Church at the Wyss Institute at Harvard.
Now, his group at Bar-Ilan University designs and studies diverse technologies inspired by nature.
They will deliver enzymes that break down cells via programmable nanoparticles.
Delivering insulin to tell cells to grow and regenerate tissue at the desired location.
Surgery would be performed by putting the programmable nanoparticles into saline and injecting them into the body to seek out remove bad cells and grow new cells and perform other medical work.
Nanoparticles with computational logic has already been done
Load an ensemble of drugs into many particles for programmed release based on situation that is found in the body
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.